SAN FRANCISCO (MarketWatch) -- AstraZeneca PLC said Monday that results from a one-year study show that patients taking its Symbicort single-inhaler therapy had fewer asthma attacks and required less ...
MADISON, Wis.--(BUSINESS WIRE)--Propeller Health, a leading digital health company dedicated to the management of asthma and COPD, today announced it has received 510(k) clearance from the U.S. Food ...
Add Yahoo as a preferred source to see more of our stories on Google. Starting Saturday, the cost of inhalers will fall for many Americans, as new out-of-pocket price caps go into effect for the ...
AstraZeneca, the UK-based maker of popular inhalers like Symbicort and Airsupra, announced Monday it plans to cap costs for patients using its inhalers in the U.S. at $35 per month starting June 1.
In the courtroom fracas over the patents on AstraZeneca’s multibillion-dollar inhaler Symbicort, Viatris and Kindeva Drug Delivery have toppled yet another intellectual property pillar. Still, ...
Findings from a trial comparing the real-world effectiveness of asthma inhalers could reshape how children with asthma are treated. In the first randomized controlled trial to investigate the use of a ...
Starting Saturday, the cost of inhalers will fall for many Americans, as new out-of-pocket price caps go into effect for the asthma medications from AstraZeneca and Boehringer Ingelheim. Following ...